IGF1R and metabolic syndrome: IGF1R-blockers have been generally documented to be well tolerated, but extended blockade of IGF1R signalling could potentially produce clinical signs and symptoms similar to those of severe untreated growth hormone deficiency, including visceral adiposity, dyslipidemia, deterioration of cardiac performance, osteoporosis, and impairment of physical and psychological performance[187,188].